161 related articles for article (PubMed ID: 2659170)
1. Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Brusa P; Pietribiasi F; Bussolati G; Dosio F; Arione R; Comoglio PM; Prat M; Cattel L
Cancer Immunol Immunother; 1989; 29(3):185-92. PubMed ID: 2659170
[TBL] [Abstract][Full Text] [Related]
2. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Brusa P; Dosio F; Pietribiasi F; Delprino L; Feraiorni P; Mariani M; Bussolati G; Cattel L
Cancer Immunol Immunother; 1992; 35(6):373-80. PubMed ID: 1394342
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice.
Brusa P; Dosio F; Pacchioni D; Delprino L; Grosa G; Bussolati G; Cattel L
J Pharm Sci; 1994 Apr; 83(4):514-9. PubMed ID: 8046606
[TBL] [Abstract][Full Text] [Related]
4. Intratumour therapy of solid tumours with ricin-antibody conjugates.
Kanellos J; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1989 Apr; 67 ( Pt 2)():89-99. PubMed ID: 2786496
[TBL] [Abstract][Full Text] [Related]
5. Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.
Cattel L; Delprino L; Brusa P; Dosio F; Comoglio PM; Prat M
Cancer Immunol Immunother; 1988; 27(3):233-40. PubMed ID: 3263208
[TBL] [Abstract][Full Text] [Related]
6. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
7. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
8. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
Rostaing-Capaillon O; Casellas P
Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138
[TBL] [Abstract][Full Text] [Related]
9. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells.
Levin LV; Griffin TW; Childs LR; Davis S; Haagensen DE
Cancer Immunol Immunother; 1987; 24(3):202-6. PubMed ID: 3496151
[TBL] [Abstract][Full Text] [Related]
10. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
11. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
14. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
15. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Schmidberger H; King L; Lasky LC; Vallera DA
Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
[TBL] [Abstract][Full Text] [Related]
17. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM
J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193
[TBL] [Abstract][Full Text] [Related]
18. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
19. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.
Blakey DC; Skilleter DN; Price RJ; Thorpe PE
Biochim Biophys Acta; 1988 Feb; 968(2):172-8. PubMed ID: 3257705
[TBL] [Abstract][Full Text] [Related]
20. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]